Combo Therapy May Be Best Option For Kidney Cancer Patients, Sponsors
Executive Summary
Developing combination regimens may provide optimal therapy for renal cell carcinoma patients and, simultaneously, allow manufacturers to avoid partitioning off the relatively limited kidney cancer market, Genentech VP-Clinical Oncology Gwen Fyfe suggested
You may also be interested in...
Targeted Combinations May Reduce Cost By Shortening Treatment
Using combinations of targeted oncologics may actually reduce the cost of treatment with the expensive cancer therapies by reducing the duration of treatment, Vanderbilt-Ingram Cancer Center's Carlos Arteaga suggested during ASCO's annual meeting in Atlanta
Targeted Combinations May Reduce Cost By Shortening Treatment
Using combinations of targeted oncologics may actually reduce the cost of treatment with the expensive cancer therapies by reducing the duration of treatment, Vanderbilt-Ingram Cancer Center's Carlos Arteaga suggested during ASCO's annual meeting in Atlanta
PTK/ZK Not Dead Yet; R&D Efforts May Shift To Subgroup, Novartis Says
Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7